Literature DB >> 33572167

A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer.

Cristina Romei1, Rossella Elisei1.   

Abstract

Thyroid carcinoma is the most frequent endocrine neoplasia. Different types of thyroid carcinoma are described: well-differentiated papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma (ATC), and medullary thyroid carcinoma (MTC). MTC is inherited as an autosomal dominant trait in 25% of cases. The genetic landscape of thyroid carcinoma has been largely deciphered. In PTC, genetic alterations have been found in about 95% of tumors: BRAF mutations and RET rearrangements are the main genetic alterations. BRAF and RAS mutations have been confirmed to play an important role also in PDTC and ATC, together with TP53 mutations that are fundamental in tumor progression. It has also been clearly demonstrated that telomerase reverse transcriptase (TERT) promoter mutations and TP53 mutations are present with a high-frequency in more advanced tumors, frequently associated with other mutations, and their presence, especially if simultaneous, is a signature of aggressiveness. In MTC, next-generation sequencing confirmed that mutations in the RET gene are the most common molecular events followed by H-RAS and K-RAS mutations. The comprehensive knowledge of the genetic events responsible for thyroid tumorigenesis is important to better predict the biological behavior and better plan the therapeutic strategy for specific treatment of the malignancy based on its molecular profile.

Entities:  

Keywords:  BRAF; RET; TERT; molecular signature; oncogenes; p53; thyroid cancer

Year:  2021        PMID: 33572167      PMCID: PMC7915177          DOI: 10.3390/ijms22041726

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  92 in total

1.  In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.

Authors:  B Cosci; A Vivaldi; C Romei; F Gemignani; S Landi; R Ciampi; A Tacito; E Molinaro; L Agate; V Bottici; V Cappagli; D Viola; P Piaggi; P Vitti; A Pinchera; R Elisei
Journal:  Endocr Relat Cancer       Date:  2011-09-20       Impact factor: 5.678

2.  RET fusion as a novel driver of medullary thyroid carcinoma.

Authors:  Elizabeth G Grubbs; Patrick Kwok-Shing Ng; Jacquelin Bui; Naifa L Busaidy; Ken Chen; Jeffrey E Lee; Xinyan Lu; Hengyu Lu; Funda Meric-Bernstam; Gordon B Mills; Gary Palmer; Nancy D Perrier; Kenneth L Scott; Kenna R Shaw; Steven G Waguespack; Michelle D Williams; Roman Yelensky; Gilbert J Cote
Journal:  J Clin Endocrinol Metab       Date:  2014-12-29       Impact factor: 5.958

3.  TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.

Authors:  Xiaoli Liu; Shen Qu; Rengyun Liu; Chunjun Sheng; Xiaoguang Shi; Guangwu Zhu; Avaniyapuram Kannan Murugan; Haixia Guan; Hongyu Yu; Yangang Wang; Hui Sun; Zhongyan Shan; Weiping Teng; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2014-03-11       Impact factor: 5.958

4.  Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.

Authors:  Raffaele Ciampi; Jeffrey A Knauf; Roswitha Kerler; Manoj Gandhi; Zhaowen Zhu; Marina N Nikiforova; Hartmut M Rabes; James A Fagin; Yuri E Nikiforov
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

5.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

Authors:  C Eng; D Clayton; I Schuffenecker; G Lenoir; G Cote; R F Gagel; H K van Amstel; C J Lips; I Nishisho; S I Takai; D J Marsh; B G Robinson; K Frank-Raue; F Raue; F Xue; W W Noll; C Romei; F Pacini; M Fink; B Niederle; J Zedenius; M Nordenskjöld; P Komminoth; G N Hendy; L M Mulligan
Journal:  JAMA       Date:  1996-11-20       Impact factor: 56.272

6.  Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience.

Authors:  Liborio Torregrossa; David Viola; Elisa Sensi; Mirella Giordano; Paolo Piaggi; Cristina Romei; Gabriele Materazzi; Paolo Miccoli; Rossella Elisei; Fulvio Basolo
Journal:  J Clin Endocrinol Metab       Date:  2016-08-29       Impact factor: 5.958

7.  Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.

Authors:  Joel Smith; Martin L Read; Jon Hoffman; Rachel Brown; Beth Bradshaw; Christopher Campbell; Trevor Cole; Johanna Dieguez Navas; Fiona Eatock; Justin S Gundara; Eric Lian; Dom Mcmullan; Neil V Morgan; Lois Mulligan; Patrick J Morrison; Mercedes Robledo; Michael A Simpson; Vicki E Smith; Sue Stewart; Richard C Trembath; Stan Sidhu; Fiona S Togneri; Naomi C Wake; Yvonne Wallis; John C Watkinson; Eamonn R Maher; Christopher J McCabe; Emma R Woodward
Journal:  Hum Mol Genet       Date:  2016-03-03       Impact factor: 6.150

8.  Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.

Authors:  Seong-Keun Yoo; Seungbok Lee; Su-Jin Kim; Hyeon-Gun Jee; Byoung-Ae Kim; Hyesun Cho; Young Shin Song; Sun Wook Cho; Jae-Kyung Won; Jong-Yeon Shin; Do Joon Park; Jong-Il Kim; Kyu Eun Lee; Young Joo Park; Jeong-Sun Seo
Journal:  PLoS Genet       Date:  2016-08-05       Impact factor: 5.917

9.  Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.

Authors:  Le Ngoc Ha; Amir Iravani; Nguyen Thi Nhung; Ngo Thi Minh Hanh; Febby Hutomo; Mai Hong Son
Journal:  Cancer Imaging       Date:  2021-01-07       Impact factor: 3.909

View more
  11 in total

1.  Epidemiology of Thyroid Cancer.

Authors:  Cari M Kitahara; Arthur B Schneider
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2022-07-01       Impact factor: 4.090

Review 2.  The Role of the Kinase Inhibitors in Thyroid Cancers.

Authors:  Francesca Cuomo; Claudio Giani; Gilda Cobellis
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

3.  TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features.

Authors:  António Castanheira; Maria João Vieira; Mafalda Pinto; Carolina Dias; Luísa Prada; Sofia Macedo; Margarida Sá Fernandes; Fortunato Vieira; Paula Soares; Alberto Mota; José Manuel Lopes; Paula Boaventura
Journal:  Sci Rep       Date:  2021-05-17       Impact factor: 4.379

4.  miR-195-5p regulates cell proliferation, apoptosis, and invasion of thyroid cancer by targeting telomerase reverse transcriptase.

Authors:  Zhiwen Liu; Li Zhang; Wen Chen; Fenqian Yuan; Zhi Yang; Sheng Liu; Fei Le
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 5.  Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.

Authors:  Svetlana N Aleksakhina; Evgeny N Imyanitov
Journal:  Int J Mol Sci       Date:  2021-10-10       Impact factor: 5.923

6.  Synchronous lateral lymph node metastases from papillary and follicular thyroid carcinoma: case report and review of the literature.

Authors:  Adam Stenman; Magnus Kjellman; Jan Zedenius; C Christofer Juhlin
Journal:  Thyroid Res       Date:  2022-02-04

7.  Diagnostic performance of next-generation sequencing and genetic profiling in thyroid nodules from a single center in China.

Authors:  Min Ren; Qianlan Yao; Longlong Bao; Zhiting Wang; Ran Wei; Qianming Bai; Bo Ping; Cai Chang; Yu Wang; Xiaoyan Zhou; Xiaoli Zhu
Journal:  Eur Thyroid J       Date:  2022-05-27

8.  FOXP4-AS1 Inhibits Papillary Thyroid Carcinoma Proliferation and Migration Through the AKT Signaling Pathway.

Authors:  Xue Luo; Qingjun Gao; Tian Zhou; Rui Tang; Yu Zhao; Qifang Zhang; Nanpeng Wang; Hui Ye; Xinghong Chen; Song Chen; Wenli Tang; Daiwei Zhao
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 9.  Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer.

Authors:  Jing Li; Yingjie Zhang; Fenghao Sun; Ligang Xing; Xiaorong Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-08       Impact factor: 6.055

10.  TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea.

Authors:  Min Jhi Kim; Jin Kyong Kim; Gi Jeong Kim; Sang-Wook Kang; Jandee Lee; Jong Ju Jeong; Woong Youn Chung; Daham Kim; Kee-Hyun Nam
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.